Celltrion launches breast cancer biosimilar in GermanyAn affiliate of Korean biopharmaceutical firm Celltrion said Tuesday that its breast cancer biosimilar has gone on sale in Germany following approval from Europe’s regulatory body.
Celltrion Healthcare, which handles Celltrion’s overseas business, said Herzuma, a drug based on Herceptin, is now available in the European country. Herceptin was originally developed by Swiss pharmaceutical giant Roche Holding.
Herzuma, which was first launched in Britain earlier this month, will be rolled out further in other European Union markets, including Italy, by the end of the second quarter, Celltrion Healthcare said. In February, the European Medicines Agency approved the sale of Herzuma for the treatment of people who tested positive during the early stages of breast cancer.